Location History:
- Naruto, JP (1996)
- Tokushima, JP (2013)
- Tokyo, JP (2016)
Company Filing History:
Years Active: 1996-2016
Title: The Innovative Contributions of Takashi Kobunai
Introduction
Takashi Kobunai, a prominent inventor based in Naruto, Japan, has made significant strides in the field of oncology through his innovative patents. With a total of five patents under his name, he has focused primarily on developing methods for cancer treatment, particularly concerning gastric cancer.
Latest Patents
Kobunai's latest contributions include a groundbreaking method for selecting chemotherapy for gastric cancer patients. This method utilizes a combination drug comprising tegafur, gimeracil, and oteracil potassium alongside an EGFR inhibitor. The invention aims to predict the therapeutic effect of this chemotherapy combination in gastric cancer patients. Additionally, another important patent focuses on predicting sensitivities to 5-fluorouracil-type anticancer agents. This method analyzes factors affecting sensitivities and uses the copy number of the dihydropyrimidine dehydrogenase gene as an indicator in predicting responses to 5-fluorouracil-based agents. Included in this patent are kits and primers designed for predicting these sensitivities.
Career Highlights
Currently, Takashi Kobunai is associated with Taiho Pharmaceutical Company Limited, a respected name in the pharmaceutical industry. His work has contributed to advances in personalized medicine, particularly in the realm of cancer treatment, showcasing his commitment to improving patient outcomes.
Collaborations
Throughout his career, Takashi Kobunai has collaborated with notable colleagues, including Tadafumi Terada and Katsuhiko Fujimoto. These partnerships have been instrumental in driving innovation and enhancing the effectiveness of therapeutic approaches in oncology.
Conclusion
In conclusion, Takashi Kobunai stands out as an influential inventor whose work has the potential to transform cancer treatment. With his patented methods aimed at improving chemotherapy selection and predicting treatment responses, his contributions to the field of oncology are both significant and impactful. His dedication to innovation continues to pave the way for advancements in cancer therapeutics.